The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers
Authors:
- Richard Y. BallRBRichard Y. Ball
- Ryan CardenasRCRyan Cardenas
- Mark S. WinterboneMWMark S. Winterbone
- Marcelino Y. HannaMHMarcelino Y. Hanna
- Chris ParkerCPChris Parker
- Rachel HurstRHRachel Hurst
- Daniel S. BrewerDaniel S. Brewer
- Lauren D’saLDLauren D’sa
- Rob MillsRMRob Mills
- Colin S. CooperCCColin S. Cooper
- Jeremy ClarkJCJeremy Clark
Open Access
Abstract
The Prostate Urine Risk (PUR) biomarker is a four-group classifier for predicting outcome in patients prior to biopsy and for men on active surveillance. The four categories correspond to the probabilities of the presence of normal tissue (PUR-1), D’Amico low-risk (PUR-2), intermediate-risk (PUR-3), and high-risk (PUR-4) prostate cancer. In the current study we investigate how the PUR-4 status is linked to Gleason grade, prostate volume, and tumor volume as assessed from biopsy (n = 215) and prostatectomy (n = 9) samples. For biopsy data PUR-4 status alone was linked to Gleason Grade group (GG) (Spearman’s, ρ = 0.58, p < 0.001 trend). To assess the impact of tumor volume each GG was dichotomized into Small and Large volume cancers relative to median volume. For GG1 (Gleason Pattern 3 + 3) cancers volume had no impact on PUR-4 status. In contrast for GG2 (3 + 4) and GG3 (4 + 3) cancers PUR-4 levels increased in large volume cancers with statistical significance observed for GG2 (p = 0.005; Games-Howell). These data indicated that PUR-4 status is linked to the presence of Gleason Pattern 4. To test this observation tumor burden and Gleason Pattern were assessed in nine surgically removed and sectioned prostates allowing reconstruction of 3D maps. PUR-4 was not correlated with Gleason Pattern 3 amount, total tumor volume or prostate size. A strong correlation was observed between amount of Gleason Pattern 4 tumor and PUR-4 signature (r = 0.71, p = 0.034, Pearson’s). These observations shed light on the biological significance of the PUR biomarker and support its use as a non-invasive means of assessing the presence of clinically significant prostate cancer.Keywords
Funding Information
- Prostate Cancer UK (RIA18-ST2-014)
- Movember Foundation (RIA18-ST2-014)
This publication has 25 references indexed in Scilit:
- Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?The Lancet Oncology, 2012
- Upgrading and Downgrading of Prostate Cancer from Biopsy to Radical Prostatectomy: Incidence and Predictive Factors Using the Modified Gleason Grading System and Factoring in Tertiary GradesEuropean Urology, 2012
- A Panel of TMPRSS2:ERG Fusion Transcript Markers for Urine-Based Prostate Cancer Detection with High Specificity and SensitivityEuropean Urology, 2010
- Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?Journal of Clinical Oncology, 2009
- Yearly Prostate Specific Antigen and Digital Rectal Examination Fluctuations in a Screened PopulationJournal of Urology, 2009
- The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancerThe Prostate, 2008
- Percent Positive Biopsy Cores as a Prognostic Factor for Prostate Cancer Treated with External Beam RadiationUrology, 2007
- Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomyCancer, 2006
- APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate CancerClinical Chemistry, 2006
- Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostateCancer, 2004